Jump to content

Serazapine

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Vanished user 0x8cSXE0x6 (talk | contribs) at 05:27, 23 August 2021. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Serazapine
Clinical data
Other namesCGS-15040A
Routes of
administration		By mouth
ATC code
  • None
Identifiers
  • methyl 2-methyl-1,3,4,16b-tetrahydro-2H,10H-benzo[5,6]pyrazino[2',1':3,4][1,4]diazepino[1,2-a]indole-16-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H23N3O2
Molar mass361.445 g·mol−1
3D model (JSmol)
  • O=C(OC)C1=C2N(C3=C1C=CC=C3)CC4=CC=CC=C4N5C2CN(C)CC5
  • InChI=1S/C22H23N3O2/c1-23-11-12-24-17-9-5-3-7-15(17)13-25-18-10-6-4-8-16(18)20(22(26)27-2)21(25)19(24)14-23/h3-10,19H,11-14H2,1-2H3 checkY
  • Key:WPGUWABWNUSPMW-UHFFFAOYSA-N checkY

Serazapine (developmental code name CGS-15040A) is a serotonin 5-HT2 receptor antagonist that was investigated as a potential treatment for generalized anxiety disorder in the 1990s. In humans, serazapine was well tolerated at doses of 10 to 40 mg and was found to be superior to placebo for reducing anxiety symptoms as indicated by HAM-A scores.[1][2] However, clinical development was discontinued.[2]

References

  1. ^ Katz RJ, Landau PS, Lott M, Bystritsky A, Diamond B, Hoehn-Saric R, et al. (1 July 1993). "Serotonergic (5-HT2) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorder". Biological Psychiatry. 34 (1–2): 41–4. doi:10.1016/0006-3223(93)90254-b. PMID 8104044. S2CID 24119589.
  2. ^ a b "Serazepine". Adis Insight. Springer Nature Switzerland AG. Retrieved 8 April 2021.


Retrieved from "https://en.wikipedia.org/w/index.php?title=Serazapine&oldid=1040199660"